Statements (25)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:biotechnology
|
| gptkbp:acquisition |
Incyte Genomics, Inc.
|
| gptkbp:ceo |
Herbert W. (Herb) Hooper
|
| gptkbp:clinical_trial |
Phase 3 trials
|
| gptkbp:employees |
~1,500
|
| gptkbp:focus |
gptkb:cancer_treatment
autoimmune diseases inflammation |
| gptkbp:founded |
gptkb:1991
|
| gptkbp:founder |
gptkb:Paul_Friedman
|
| gptkbp:headquarters |
gptkb:Wilmington,_Delaware
|
| https://www.w3.org/2000/01/rdf-schema#label |
Incyte Biosciences, Inc.
|
| gptkbp:industry |
gptkb:pharmaceuticals
|
| gptkbp:partnership |
gptkb:Medi_Wound
gptkb:Bristol-Myers_Squibb gptkb:Novartis |
| gptkbp:products |
gptkb:Iclusig
gptkb:Jakafi gptkb:Pemigatinib |
| gptkbp:revenue |
$1.1 billion (2020)
|
| gptkbp:subsidiary |
gptkb:Incyte_Corporation
|
| gptkbp:traded_on |
gptkb:NASDAQ
|
| gptkbp:website |
www.incyte.com
|
| gptkbp:bfsParent |
gptkb:Incyte_Corporation
|
| gptkbp:bfsLayer |
5
|